non-invasive sagging skin treatment glp-1 no downtime Quantum RF Tightening- Surgical results with Powered by our patent Managing Skin Laxity During GLP-1

Refrigerate at 2 to 8 degrees Celsius, protect from light, and never freeze reconstituted solutions

GLP-1(736)-amide and exendin-4 stimulate the HPA axis in rodents and humans

Trial Structure Duration: 48 weeks of treatment Participants: 338 adults randomized 2:1:1:1:1:2:2 to placebo or retatrutide groups Doses tested: 1mg, 4mg, 8mg, 12mg (all with slow titration from 2mg starting dose) Lifestyle intervention: All participants received counseling on diet (500 kcal/day deficit) and exercise (150 min/week) Primary endpoint: Percent weight change at 24 weeks Key secondary endpoints: Weight change at 48 weeks, proportion achieving 5%, 10%, 15% loss The trial used a slow titration protocol to minimize side effects: all groups except the 1mg dose started at 2mg weekly and escalated every 4 weeks

Amer, A

But there was one problem

How do I know for sure if my peptide has degraded